Medline Posts Mixed Q4 Results Amid Tariff Pressures and IPO Costs
Event summary
- Medline reported Q4 net sales of $7.8B, up 14.8% YoY, but net income fell 37.7% due to tariffs and IPO-related expenses.
- Full-year 2025 revenue hit $28.4B (+11.5%), with adjusted EBITDA rising 3.2% to $3.5B.
- Completed its initial public offering, becoming a publicly traded company on Nasdaq (MDLN).
- Guidance for 2026 projects 8-9% organic sales growth and adjusted EBITDA of $3.5-$3.6B.
The big picture
Medline's mixed Q4 results reflect broader challenges in the medical-surgical supply chain, including tariff impacts and rising operational costs. As a newly public company, it faces pressure to balance growth with profitability while navigating heightened regulatory and market expectations. The healthcare distribution sector continues to consolidate, making scale and efficiency critical for long-term success.
What we're watching
- Cost Management
- How Medline will mitigate tariff and operational cost pressures while maintaining growth.
- IPO Aftermath
- Whether the company can sustain momentum post-IPO with heightened public scrutiny.
- Market Expansion
- The pace at which Medline integrates new customers and expands its supply chain solutions segment.
Our editorial coverage:
Related topics